Addressing Metabolic Risk in Schizophrenia

People living with schizophrenia spectrum disorders (SSDs) frequently face severe metabolic challenges. Antipsychotic medications often lead to rapid weight gain and insulin resistance. Consequently, this population suffers from significantly higher morbidity rates compared to the general public. Semaglutide for schizophrenia is emerging as a critical intervention to combat these metabolic side effects.

Efficacy of Semaglutide for Schizophrenia

A recent meta-analysis of three randomized controlled trials examined the impact of semaglutide dosages ranging from 1.0 to 2.0 mg. The results showed that semaglutide significantly reduced body weight by an average of 11.32 kg over 26 to 36 weeks. Additionally, participants experienced a decrease in body mass index (BMI) by 3.58 kg/m². Beyond weight, semaglutide improved glycemic markers, lowering haemoglobin A1c by 0.37% and fasting glucose by 0.54 mmol/L. These findings suggest that GLP-1 receptor agonists provide a robust metabolic lifeline for psychiatric patients.

Safety and Adverse Event Profile

While the efficacy is clear, clinicians must monitor for gastrointestinal side effects. The analysis revealed that semaglutide was associated with an increased risk of abdominal pain, vomiting, and constipation. Specifically, the risk of constipation was more than three times higher in the treatment group. However, there was no evidence of an increased risk of serious adverse events. Therefore, semaglutide remains a safe and promising adjunctive treatment for metabolic dysfunction in this vulnerable population.

The Need for Longer Trials

Current evidence supports semaglutide as a viable tool for managing weight in SSD patients. However, the study highlights a lack of data for other agents like tirzepatide. Researchers emphasize the need for larger and longer trials to fully understand long-term safety. Future studies should also explore how these treatments affect different patient subgroups to minimize heterogeneity in clinical outcomes.

Frequently Asked Questions

How effective is semaglutide for schizophrenia-related weight gain?

Studies show that semaglutide can lead to a weight reduction of over 11 kg in patients with schizophrenia spectrum disorders. This is particularly relevant for those taking second-generation antipsychotics that cause weight gain.

Are there serious side effects when using semaglutide in psychiatric patients?

Current meta-analyses suggest no increased risk of serious adverse events. The primary side effects are gastrointestinal, such as nausea, vomiting, and constipation, which are usually mild to moderate.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Trott M et al. The safety and efficacy of semaglutide in people with schizophrenia spectrum disorders: systematic review and meta-analysis of randomised controlled trials. BJPsych Open. 2026 May 25. doi: 10.1192/bjo.2026.12001. PMID: 42179170.


2. Sass M et al. Semaglutide and Early-Stage Metabolic Abnormalities in Individuals With Schizophrenia Spectrum Disorders. JAMA Psychiatry. 2025 Dec. doi:10.1001/jamapsychiatry.2025.3456.


3. Khaity A et al. GLP-1 receptor agonists for cardiometabolic parameters in schizophrenia: a systematic review and meta-analysis. Front Psychiatry. 2023;14:1153648.